Business
Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results
Topline results from the OV329 Phase 1 safety, tolerability and biomarker study remain on track for a readout in Q3 2025$7.0 million royalty monetization agreement signed with Immedica Pharma AB for future ganaxolone royalties, delivering capital to the Company from a non-pipeline assetOV4071, the first ever oral KCC2 direct activator, is completing an IND-enabling package; Ovid anticipates first-in-human studies in Q2 2026Cash, cash equivalents and marketable securities of $38.3 million as of J
About this update from Ovid Therapeutics Inc.
[{"type":"image","alt":"Ovid Therapeutics Inc.","displaySize":"","headline":null,"caption":"Ovid Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":142,"url":"https://media.zenfs.com/en/globenewswire.com/baa9b4878fad6bda7fe19181be40a802"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/27DLXferaeZxhRE9vCTuYA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5OTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/baa9b4878fad6bda7fe19181be40a802","width":300,"height":142}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Topline results from the OV329 Phase 1 safety, tolerability and biomarker study remain on track for a readout in Q3 2025","length":120,"tagName":"p"}]},{"val":[{"type":"text","content":"$7.0 million royalty monetization agreement signed with Immedica Pharma AB for future ganaxolone royalties, delivering capital to the Company from a non-pipeline asset","length":167,"tagName":"p"}]},{"val":[{"type":"text","content":"OV4071, the first ever oral KCC2 direct activator, is completing an IND-enabling package; Ovid anticipates first-in-human studies in Q2 2026","length":140,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash, cash equivalents and marketable securities of $38.3 million as of June 30, 2025 are expected to support currently planned operations and development programs into early 2H 2026","length":182,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":609,"olType":false},{"type":"text","content":"NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, today reported business updates and financial results for the second quarter ended June 30, 2025.","length":307,"tagName":"p"},{"type":"text","content":"“Our pipeline continues to advance across multiple fronts, with several key readouts anticipated in the near and mid-term. We are on track to share Phase 1 safety, tolerability, and biomarker data for OV329, a potential best-in-class medicine for conditions driven by excess neuronal excitation, including treatment-resistant seizures and pain,” said Dr. Jeremy Levin, D.Phil., MB BChir., Chairman and CEO of Ovid Therapeutics. “Simultaneously, our KCC2 program is advancing well. We expect to read out safety...